Abstract
Angiotensin II, the primary active hormone in the Renin-Angiotensin System is a major vasoconstrictor implicated in the cause of hypertension. Research efforts have focused in the treatment of disease by blocking its release and more recently by competing its action on AT 1 receptors. This approach generated in the pharmaceutical market, losartan, and other derivatives. To better understand the stereoelectronic requirements that lead to the molecular basis of hypertension the stereochemical features of angiotensin II and its antagonists are studied.
Keywords: Antihypertensive Drugs, Renin-Angiotensin System, AT1 Antagonists, Angiotensin, RENIN ANGIOTENSIN SYSTEM, ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, RENIN INHIBITORS, Captopril, Enlapril, Remikiren
Mini-Reviews in Medicinal Chemistry
Title: Antihypertensive Drugs that Act on Renin-Angiotensin System with Emphasis in AT1 Antagonists
Volume: 1 Issue: 2
Author(s): T. Mavromoustakos, V. Apostolopoulos and J. Matsoukas
Affiliation:
Keywords: Antihypertensive Drugs, Renin-Angiotensin System, AT1 Antagonists, Angiotensin, RENIN ANGIOTENSIN SYSTEM, ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, RENIN INHIBITORS, Captopril, Enlapril, Remikiren
Abstract: Angiotensin II, the primary active hormone in the Renin-Angiotensin System is a major vasoconstrictor implicated in the cause of hypertension. Research efforts have focused in the treatment of disease by blocking its release and more recently by competing its action on AT 1 receptors. This approach generated in the pharmaceutical market, losartan, and other derivatives. To better understand the stereoelectronic requirements that lead to the molecular basis of hypertension the stereochemical features of angiotensin II and its antagonists are studied.
Export Options
About this article
Cite this article as:
Mavromoustakos T., Apostolopoulos V. and Matsoukas J., Antihypertensive Drugs that Act on Renin-Angiotensin System with Emphasis in AT1 Antagonists, Mini-Reviews in Medicinal Chemistry 2001; 1 (2) . https://dx.doi.org/10.2174/1389557013407115
DOI https://dx.doi.org/10.2174/1389557013407115 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Co-Editor
Current Vascular Pharmacology Targeting NO Signaling for the Treatment of Osteoporosis
Current Medicinal Chemistry MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Conference Report (The XVth International Symposium of Brain Edema and Cellular Injury)
CNS & Neurological Disorders - Drug Targets Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Antihyperglycemic and Antidyslipidemic Activities of the <i>Aqueous Salvia hispanica</i> Extract in Diabetic Rat
Cardiovascular & Hematological Agents in Medicinal Chemistry Meet Our Editor:
Current Clinical Pharmacology Alzheimers Disease, Ceramide, Visfatin and NAD
CNS & Neurological Disorders - Drug Targets Protective Effect of α-ketobutyrate on Survival of Hippocampal Neurons Challenged with Hydrogen Peroxide Chemistry Mimicking Brain Ischemia
Current Pharmaceutical Analysis 1+1 > 2: Integration of the Host-directed Traditional Chinese Medicine and the Virus-targeted Modern Medicine in Control of COVID-19
Clinical Cancer Drugs Thiazide Diuretics: 50 Years and Beyond
Current Hypertension Reviews Antioxidants in the Treatment of Diabetes
Current Diabetes Reviews Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients
Current Pharmaceutical Biotechnology Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)
Current Vascular Pharmacology Gene-Gene and Gene-Environment Interplay Represent Specific Susceptibility for Different Types of Ischaemic Stroke and Leukoaraiosis
Current Medicinal Chemistry Clinical Uses of 1-Alpha-Hydroxy-Ergocalciferol
Current Vascular Pharmacology Medicinal Properties of Mangiferin, Structural Features, Derivative Synthesis, Pharmacokinetics and Biological Activities
Mini-Reviews in Medicinal Chemistry Potential Applications of RNA Interference-Based Therapeutics in the Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and ‘Practical’ Indications in Patients Receiving Carfilzomib
Current Hypertension Reviews Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry